Xuan Gu Bao·2025-06-09 14:57Group 1: HPV Vaccine Market Overview - The HPV vaccine market in China grew from 940 million yuan in 2017 to 13.56 billion yuan in 2020, with a compound annual growth rate (CAGR) of 143.43% [1] - The global HPV vaccine market is expected to achieve a CAGR of 20.04% from 2020 to 2025, potentially reaching 16.8 billion USD by 2031 [2] Group 2: Policy and Market Drivers - The Chinese government is promoting inclusive development and prioritizing children's welfare, which includes enhancing HPV vaccination efforts among eligible girls [1] - The demand for HPV vaccines is anticipated to accelerate due to policy support and the rapid growth of domestic vaccine companies [2] Group 3: Company Developments - Wantai Biological Pharmacy's subsidiary, Xiamen Wantai Canghai, has received approval from the National Medical Products Administration for its nine-valent HPV vaccine, making it the first in China and the second globally [3] - Watson Bio's subsidiary, Shanghai Zerun, is advancing its phase III clinical trials for a nine-valent HPV vaccine, currently in the data analysis and clinical research report writing phase [3]